Treatments for COVID-19: emerging drugs against the coronavirus - reply
Keywords:
COVID-19, emerging drugs, replyAbstract
.
References
1. Potì F, Pozzoli C, Adami M, Poli E, Costa LG. Treatments for covid-19: Emerging drugs against the coronavirus. Acta Biomed. 2020;91(2):118-136. doi:10.23750/abm.v91i2.9639
2. de Haan CAM, Rottier PJM. Molecular Interactions in the Assembly of Coronaviruses. Adv Virus Res. 2005;64:165-230. doi:10.1016/S0065-3527(05)64006-7
3. de Wilde AH, Wannee KF, Scholte FEM, et al. A Kinome-Wide Small Interfering RNA Screen Identifies Proviral and Antiviral Host Factors in Severe Acute Respiratory Syndrome Coronavirus Replication, Including Double-Stranded RNA-Activated Protein Kinase and Early Secretory Pathway Proteins. J Virol. 2015;89(16):8318-8333. doi:10.1128/jvi.01029-15
4. Rodrigo R. R. D, Dennis C. CJ, Luis P. I, Jez L. M, Douglas F. N, Timothy R. P. Repurposing FDA-Approved Drugs for COVID-19 Using a Data-Driven Approach. chemRxiv. April 2020. doi:10.26434/chemrxiv.12148764.v1
5. Wu CY, Jan JT, Ma SH, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A. 2004;101(27):10012-10017. doi:10.1073/pnas.0403596101
6. Shamon SD, Perez MI. Blood pressure-lowering efficacy of reserpine for primary hypertension. Cochrane Database Syst Rev. 2016;2016(12). doi:10.1002/14651858.CD007655.pub3
7. Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database Syst Rev. 2018;2018(4). doi:10.1002/14651858.CD001841.pub3
8. Webster J, Koch HF. Aspects of tolerability of centrally acting antihypertensive drugs. In: Journal of Cardiovascular Pharmacology. Vol 27. Lippincott Williams and Wilkins; 1996. doi:10.1097/00005344-199627003-00007
2. de Haan CAM, Rottier PJM. Molecular Interactions in the Assembly of Coronaviruses. Adv Virus Res. 2005;64:165-230. doi:10.1016/S0065-3527(05)64006-7
3. de Wilde AH, Wannee KF, Scholte FEM, et al. A Kinome-Wide Small Interfering RNA Screen Identifies Proviral and Antiviral Host Factors in Severe Acute Respiratory Syndrome Coronavirus Replication, Including Double-Stranded RNA-Activated Protein Kinase and Early Secretory Pathway Proteins. J Virol. 2015;89(16):8318-8333. doi:10.1128/jvi.01029-15
4. Rodrigo R. R. D, Dennis C. CJ, Luis P. I, Jez L. M, Douglas F. N, Timothy R. P. Repurposing FDA-Approved Drugs for COVID-19 Using a Data-Driven Approach. chemRxiv. April 2020. doi:10.26434/chemrxiv.12148764.v1
5. Wu CY, Jan JT, Ma SH, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A. 2004;101(27):10012-10017. doi:10.1073/pnas.0403596101
6. Shamon SD, Perez MI. Blood pressure-lowering efficacy of reserpine for primary hypertension. Cochrane Database Syst Rev. 2016;2016(12). doi:10.1002/14651858.CD007655.pub3
7. Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database Syst Rev. 2018;2018(4). doi:10.1002/14651858.CD001841.pub3
8. Webster J, Koch HF. Aspects of tolerability of centrally acting antihypertensive drugs. In: Journal of Cardiovascular Pharmacology. Vol 27. Lippincott Williams and Wilkins; 1996. doi:10.1097/00005344-199627003-00007
Downloads
Published
07-09-2020
Issue
Section
CORRESPONDENCE/CASE REPORTS - SPECIAL COVID19
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
1.
Potì F. Treatments for COVID-19: emerging drugs against the coronavirus - reply. Acta Biomed. 2020;91(3):e2020049. doi:10.23750/abm.v91i3.10108
